Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts

Journal of Cellular Physiology

Volumn 226, Issue 12, 2011, Pages 3340-3348

  Morris, Erin ^a   Chrobak, Izabela ^b   Bujor, Andreea ^b   Hant, Faye ^a   Mummery, Christine ^c   ten Dijke, Peter ^c   Trojanowska, Maria ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; ENDOGLIN; MESSENGER RNA; SMAD1 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE II; ANTIGENS, CD; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN-1; ENZYME ACTIVATION; FIBROBLASTS; FIBROSIS; HEK293 CELLS; HUMANS; MUTATION; PHENOTYPE; PHOSPHORYLATION; RECEPTORS, CELL SURFACE; RNA INTERFERENCE; RNA, MESSENGER; SCLERODERMA, DIFFUSE; SIGNAL TRANSDUCTION; SKIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 79960105125     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22690     Document Type: Article

References (48)

1. Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL. 1993. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75: 671-680.
2. Barbara NP, Wrana JL, Letarte M. 1999. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584-594.
3. Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, et al. 2006. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 95: 1683-1688.
4. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, et al. 2005. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204: 574-584.
5. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, et al. 2000. Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol 96: 224-228.
6. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, et al. 1992. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030.
7. Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, et al. 2006. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 54: 1309-1316.
8. Clemente M, Nunez O, Lorente R, Rincon D, Matilla A, et al. 2006. Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: Relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat 13: 625-632.
9. Coral-Alvarado PX, Garces MF, Caminos JE, Iglesias-Gamarra A, Restrepo JF, et al. Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol 2010.
10. Daly AC, Randall RA, Hill CS. 2008. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28: 6889-6902.
11. David L, Mallet C, Vailhe B, Lamouille S, Feige JJ, et al. 2007. Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: Potential roles for JNK and ERK. J Cell Physiol 213: 484-489.
12. Dharmapatni AA, Smith MD, Ahern MJ, Simpson A, Li C, et al. 2001. The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 19: 275-282.
13. Diez-Marques L, Ortega-Velazquez R, Langa C, Rodriguez-Barbero A, Lopez-Novoa JM, et al. 2002. Expression of endoglin in human mesangial cells: Modulation of extracellular matrix synthesis. Biochim Biophys Acta 1587: 36-44.
14. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, et al. 2007. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127: 572-579.
15. Farina G, York M, Collins C, Lafyatis R. 2011. dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Ann Rheum Dis 70: 544-550.
16. Finnson KW, Parker WL, Chi Y, Hoemann CD, Goldring MB, et al. 2010. Endoglin differentially regulates TGF-beta-induced Smad2/3 and Smad1/5 signalling and its expression correlates with extracellular matrix production and cellular differentiation state in human chondrocytes. Osteoarthritis Cartilage 18: 1518-1527.
17. Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, et al. 2006. A clue for telangiectasis in systemic sclerosis: Elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 213: 88-92.
18. Gabrielli A, Avvedimento EV, Krieg T. 2009. Scleroderma. N Engl J Med 360: 1989-2003.
19. Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, Garcia-Arroyo A, Garcia-Sanchez A, et al. 1995. Vascular adhesion molecule expression in viral chronic hepatitis: Evidence of neoangiogenesis in portal tracts. Gastroenterology 108: 231-241.
20. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, et al. 2002. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753.
21. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, et al. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12: 817-828.
22. Groenendijk BC, Benus GF, Klous A, Pacheco YM, Volger OL, et al. 2011. Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-beta. Exp Cell Res 317: 131-142.
23. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. 2002. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 277: 29197-29209.
24. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. 1998. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514.
25. Leask A. 2008. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 20: 1409-1414.
26. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, et al. 2002. Dysregulation of transforming growth factor beta signaling in scleroderma: Overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 46: 1857-1865.
27. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, et al. 2004. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23: 4018-4028.
28. Lux A, Salway F, Dressman HK, Kroner-Lux G, Hafner M, et al. 2006. ALK1 signalling analysis identifies angiogenesis related genes and reveals disparity between TGF-beta and constitutively active receptor induced gene expression. BMC Cardiovasc Disord 6: 13.
29. Meurer SK, Tihaa L, Borkham-Kamphorst E, Weiskirchen R. 2011. Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal 23: 683-699.
30. Obreo J, Diez-Marques L, Lamas S, Duwell A, Eleno N, et al. 2004. Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem 14: 301-310.
31. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, et al. 2000. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631.
32. Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M. 2006. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum 54: 3011-3021.
33. Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, et al. 2008. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 58: 2528-2537.
34. Pimanda JE, Chan WY, Donaldson IJ, Bowen M, Green AR, et al. 2006. Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer. Blood 107: 4737-4745.
35. Rodriguez-Pena A, Eleno N, Duwell A, Arevalo M, Perez-Barriocanal F, et al. 2002. Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 40: 713-720.
36. Roy-Chaudhury P, Simpson JG, Power DA. 1997. Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Exp Nephrol 5: 55-60.
37. Scharpfenecker M, Floot B, Russell NS, Ten Dijke P, Stewart FA. 2009. Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. Radiother Oncol. 92: 481-493.
38. Shi Y, Massague J. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
39. Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, et al. 2006. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: Evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 26: 5518-5527.
40. Sibai B, Dekker G, Kupferminc M. 2005. Pre-eclampsia. Lancet 365: 785-799.
41. ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, et al. 1994. Characterization of type I receptors for transforming growth factor-beta and activin. Science 264: 101-104.
42. ten Dijke P, Goumans MJ, Pardali E. 2008. Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89.
43. Trojanowska M. 2009. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 21: 623-629.
44. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, et al. 2003. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 4: 609-615.
45. Velasco S, Alvarez-Munoz P, Pericacho M, Dijke PT, Bernabeu C, et al. 2008. L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 121: 913-919.
46. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. 2002. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51: 268-275.
47. Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, et al. 2008. Disturbed angiogenesis in systemic sclerosis: High levels of soluble endoglin. Rheumatology (Oxford) 47: 972-975.
48. Masi AT. 1980. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23: 581-590.